Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
78.77
+2.97 (3.92%)
At close: Feb 17, 2026, 4:00 PM EST
79.45
+0.68 (0.86%)
After-hours: Feb 17, 2026, 4:39 PM EST
Inhibrx Biosciences Revenue
In the year 2024, Inhibrx Biosciences had annual revenue of $200.00K, down -88.89%.
Revenue (ttm)
$200.00K
Revenue Growth
-88.89%
P/S Ratio
824.63
Revenue / Employee
$8,696
Employees
161
Market Cap
1.15B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 200.00K | -1.60M | -88.89% |
| Dec 31, 2023 | 1.80M | -392.00K | -17.88% |
| Dec 31, 2022 | 2.19M | -5.04M | -69.69% |
| Dec 31, 2021 | 7.23M | -5.66M | -43.89% |
| Dec 31, 2020 | 12.89M | -323.00K | -2.44% |
| Dec 31, 2019 | 13.21M | 4.62M | 53.71% |
| Dec 31, 2018 | 8.60M | 204.00K | 2.43% |
| Dec 31, 2017 | 8.39M | 1.72M | 25.86% |
| Dec 31, 2016 | 6.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 362.27M |
| Xeris Biopharma Holdings | 266.14M |
| Iovance Biotherapeutics | 250.43M |
| Geron | 183.40M |
| Day One Biopharmaceuticals | 133.67M |
| EyePoint | 42.34M |
| Vir Biotechnology | 16.86M |
| Capricor Therapeutics | 11.13M |
INBX News
- 26 days ago - These 20 stocks are strong choices for momentum investors - Market Watch
- 5 weeks ago - Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too - Seeking Alpha
- 7 weeks ago - Why Inhibrx's Recent Strength May Not Be Built to Last - Benzinga
- 2 months ago - Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program - PRNewsWire
- 3 months ago - Inhibrx Reports Third Quarter 2025 Financial Results - PRNewsWire
- 3 months ago - Inhibrx Announces Participation in Upcoming Scientific Conferences - PRNewsWire
- 4 months ago - Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing - Seeking Alpha
- 4 months ago - Inhibrx shares surge after bone cancer drug slows disease progression in trial - Reuters